Exploring the use of NGS testing in metastatic TNBC and a payer perspective on use of the appropriate companion diagnostic. Transcript Hope S. Rugo, MD: That leads us into the idea of NGS ...
Two abstracts involving real-world data (RWD) presented at the 2021 American Society of Clinical Oncology Quality Care Symposium tracked the uptake of next-generation sequencing (NGS) and biomarker ...
Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations ...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...
On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a national coverage determination (NCD) for next-generation sequencing (NGS) tests for cancer, marking a significant ...
NASHVILLE, Tenn., May 25, 2023 /PRNewswire/ -- At the 2023 ASCO annual meeting, investigators from OneOncology's clinical team will present Oral Abstracts using real-world data to evidence better ...
Clinical genomics soon may be set ablaze by whole-exome and whole-genome sequencing. Next-generation sequencing (NGS) not only continues to make steady advances in the molecular diagnosis of cancers, ...
Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.
The youngest population under 50 years old (P50) with lung cancer (LC) in the French nationwide real-life KBP cohorts: Evolution since 2000. Clinical outcomes of maintenance durvalumab after ...
Announces majority investment in NGS bioinformatics solution provider Ridom GmbH New NGS microbiology solutions for hygiene testing and epidemiological studies HAI (Hospital-Acquired Infections) ...
GMP-qualified NGS adventitious virus detection with a predictable 28-day turnaround and U.S.-based end-to-end support PHILADELPHIA, March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...
Quest Diagnostics Incorporated DGX recently announced that the company is now offering the liquid biopsy-based Target Selector NGS Lung Panel test developed by Biocept BIOC. The addition of this blood ...